The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The exponential growth in the world's aged population has increased pressure on drug discovery efforts to identify innovative therapies for Alzheimer's disease (AD). The long and uncertain clinical trial path utilized to test the potential efficacy of these novel agents is challenging. For these and other reasons, there has been an explosion in the generation and availability of transgenic mouse models that mimic some, but not all aspects of AD. The largely overwhelmingly positive results obtained when testing potential clinical agents in these same animal models have failed to translate into similar positive clinical outcomes. AREAS COVERED: This review discusses the value and limitations associated with currently available transgenic mouse models of AD. Furthermore, the article proposes ways in which researchers can better characterize pharmacodynamic and pharmacokinetic endpoints to increase the success rate for novel therapies advancing into clinical development. Lastly, the author discusses ways in which researchers can supplement, expand and improve transgenic mouse models used in AD drug discovery. EXPERT OPINION: The use of transgenic mouse models that recapitulate various aspects of AD has expanded our knowledge and understanding of disease pathogenesis immensely. Further success in testing and translating novel therapies from animal models into bona fide medicines would be enhanced by i) the availability of better models that more fully recapitulate the disease spectrum, ii) defining and measuring standardized endpoints that display a pharmacodynamic range, iii) building and including translatable biomarkers and iv) including novel endpoints that would be expected to translate into clinically beneficial outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“The exception to the presentation of these milder phenotypes is the robust and aggressive neuropathology observed in transgenic mice that over-express more than one gene associated with FAD [7-9].”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 3×
“Significant progress in understanding the pathophysiological mechanisms associated with sporadic AD has been derived from studying autosomal dominant familial forms of AD that result from the inheritance of mutations found in three genes: amyloid precursor protein (APP), Presenilin-1 (PS1) and Presenilin-2 (PS2) [19,2…”
BackgroundTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 2×
“The identification of mutations within the microtubule-associated protein tau (MAPT) gene that are causative to frontotemporal dementia (FTD) without accumulation of Ab in brain established a causative role for hyperphosphorylated tau in dementia [26].”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Using stable isotope labeling kinetics (SILK), Bateman and colleagues [44] have now demonstrated that AD subjects show no difference in the de novo synthesis rates of Ab but rather have a significant decrease in the fractional clearance rate of Ab [44,45].”
MethodBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 3×
“In support of this proposal, a significant amount of anti-Ab antibody decorating plaques has been observed [47,75].”
BackgroundThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 2×
“Additional transgenic mouse studies support that Ab may interact with endogenous tau to mediate neuronal dysfunction that manifests at the behavioral level [32].”
BackgroundMucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“Although many FAD APP transgenic mouse models do not show overt neuronal loss, synaptic loss has been reported in different models [55].”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 9×
“In addition to using immunohistochemical techniques to characterize and quantify various brain pathologies, it is now a matter of routine to also measure biochemical correlates of these neuropathological features in brain homogenates or cerebrospinal fluid (CSF; Figure 1, [10]).”
BackgroundInfluentialPalop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653 · cited 2×
“Additionally APP transgenic mice have demonstrated that even slight aberrations at select synapses may have profound effects on neuronal connectivity patterns resulting in overall hyperexcitability [57].”
BackgroundDistinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“Followup autopsy analysis of subjects in the AN1792 trial who had generated measurable titers against Ab42 demonstrated a striking removal of Ab from brain parenchyma as well as amelioration of neurite abnormalities and hippocampal tau pathology similar to the results documented in preclinical animal studies [72,73].”
ResultDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Self-citationHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 2×
“Using sensitive ISF Ab measurements, bigenic mice expressing APP and human apoE4 but not apoE3 have a prolonged half-life of extracellular Ab [51].”
BackgroundSelf-citationSperling, R. A., LaViolette, P. S., O'Keefe, K., O'Brien, J., Rentz, D. M., Pihlajamaki, M., Marshall, G., Hyman, B. T., Selkoe, D. J., Hedden, T., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.07.003 · Cited by 1,027 · cited 1×
“These results are quite congruent with emerging fMRI data from older, cognitively normal individuals who have evidence of brain amyloid deposition and who demonstrate a lack of connectivity in the default mode network that includes regions of the hippocampus and medial temporal lobe [58].”
ResultHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“3 Dominant role for clearance of brain-derived Ab by apolipoprotein E An important and surprising role of apolipoprotein E (apoE) in promoting the clearance of Ab from brain was elucidated by crossing transgenic mice that over-express APP mutations to mice that express each of the three isoforms of the human apoE gene…”
BackgroundSelf-citationImmunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“Although promising, these initial results should be tempered by the observation of an increased incidence in the appearance of vasogenic edema that was most prominent in apolipoprotein E4 carrier subjects receiving the highest dose of bapineuzumab [82,83].”
ResultOddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Prion-like mechanisms in neurodegenerative diseases
Frost, B., & Diamond, M. I. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2786 · Cited by 776 · cited 1×
“More intriguingly is the possibility that various amyloid protein aggregates (prion, tau, a-synuclein, Ab) associated with neurodegenerative disorders may also ‘imprint’ each other contributing and leading to subsequent ‘spreading’ of an NFT phenotype [38,39].”
BackgroundA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · cited 4×
“In aggregate, there are now well more than 100 gene mutations, the majority of which are located in PS1, which are associated with FAD [19].”
BackgroundInfluentialRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Animal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · cited 1×
“A further delineation of how Ab and hyperphosphorylated tau, two defining neuropathological characteristics identified in AD brain, may interact occurred when APP and tau transgenic mice were crossed resulting in the clear exacerbation of the NFT phenotype [26-28].”
BackgroundNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563
Self-citationTesting the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Haughey, N. J., Nath, A., Chan, S. L., Borchard, A. C., Rao, M. S., & Mattson, M. P. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01267.x · Cited by 466 · cited 2×
“Some of the variation in neurogenesis in the different animal models may also arise from differential effects on neurogenesis of APP metabolites such that Ab may reduce survival of progenitor cells [61], whereas soluble fragments of APP such as sAPPa may promote neurogenesis.”
BackgroundResultProteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455 · cited 1×
“Significant progress has occurred in our understanding of how APP is metabolized with the identification and characterization of the aspartyl proteases (b-APP-cleaving enzyme: BACE and g-secretase) that are responsible for the sequential cleavage of APP into Ab peptides [22].”
BackgroundNeuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433 · cited 1×
“Both APP and tau transgenic mice develop pathology that is accompanied by microglial and astroglial activation as well as cytokine production [88].”
BackgroundShaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433 · cited 1×
“Glial activation has been shown to reduce plaque pathology by a mechanism involving an increased Ab clearance [89-93].”
BackgroundMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 2×
“Preliminary encouraging results in small Phase II trials with bapineuzumab or gantenerumab using carbon-11-labeled PittsburghCompound B ((11)C-PIB) positron emission tomography (PET) suggest that both of these agents are affecting removal of Ab from brain [79,80].”
BackgroundResultCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394 · cited 1×
“These results are similar to those reported for ISF Ab levels in APP mutant mice and indicate that the appearance of NFT pathology, like Ab plaques, resulted in a decrease in the levels of the soluble ISF protein pool [37].”
ResultSelf-citationSheng, J. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00069-x · Cited by 388 · cited 1×
“However, microglia may also produce detrimental pro-inflammatory cytokines that impede efficient Ab clearance, promote tau phosphorylation, neuronal injury and cognitive impairment [94-96].”
BackgroundIntraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease
Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372
Yamada, K., Cirrito, J. R., Stewart, F. R., Jiang, H., Finn, M. B., Holmes, B. B., Binder, L. I., Mandelkow, E.-M., Diamond, M. I., Lee, V. M.-Y., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2569-11.2011 · Cited by 351
Dong, H., Goico, B., Martin, M., Csernansky, C. A., Bertchume, A., & Csernansky, J. G. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.040 · Cited by 342 · cited 1×
“Decreased neurogenesis in the hippocampus of adult APP transgenic mice has been reported in several studies whereas other studies have reported an increase in neurogenesis in transgenic mice [60-66].”
ResultMaeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., Staufenbiel, M., Iwata, N., Ono, M., Saido, T. C., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0673-07.2007 · Cited by 300 · cited 1×
“In this respect, transgenic mouse models have enabled profiling of neuroinflammatory changes during the development of plaque and NFT pathology [97-99].”
BackgroundRiemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238
AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice
Chang, E. H., Savage, M. J., Flood, D. G., Thomas, J. M., Levy, R. B., Mahadomrongkul, V., Shirao, T., Aoki, C., & Huerta, P. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507313103 · Cited by 225 · cited 1×
“Indeed, transgenic mice that have been engineered to express human APP and PS sequences at endogenous levels demonstrate a lower level of Ab accumulation but show altered neuronal phenotypes [134].”
BackgroundBoissonneault, V., Filali, M., Lessard, M., Relton, J., Wong, G., & Rivest, S. (2008) · Brain · doi:10.1093/brain/awn331 · Cited by 221 · cited 1×
“Glial activation has been shown to reduce plaque pathology by a mechanism involving an increased Ab clearance [89-93].”
BackgroundChen, K., Iribarren, P., Hu, J., Chen, J., Gong, W., Cho, E. H., Lockett, S., Dunlop, N. M., & Wang, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508125200 · Cited by 214 · cited 1×
“Glial activation has been shown to reduce plaque pathology by a mechanism involving an increased Ab clearance [89-93].”
BackgroundThe potential of functional MRI as a biomarker in early Alzheimer's disease
Sperling, R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.009 · Cited by 187 · cited 2×
“For instance, emerging evidence in humans suggests that measuring brain network activity may be an early and measurable endpoint in individuals that are genetically susceptible to AD [130,131] Relatively young individuals that are apoE4 carriers have enhanced brain network activity in the medial temporal lobe along wi…”
BackgroundWirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.-U., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0557-5 · Cited by 174 · cited 1×
“In this regard, recent models that express biochemically modified forms of Ab, that is, pyroglutamate Ab, appear to cause a more profound and robust neurodegenerative phenotype [132,133].”
BackgroundPerez-Cruz, C., Nolte, M. W., van Gaalen, M. M., Rustay, N. R., Termont, A., Tanghe, A., Kirchhoff, F., & Ebert, U. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6142-10.2011 · Cited by 172
Song, S.-K., Kim, J. H., Lin, S.-J., Brendza, R. P., & Holtzman, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.003 · Cited by 170
Serrano-Pozo, A., William, C. M., Ferrer, I., Uro-Coste, E., Delisle, M.-B., Maurage, C.-A., Hock, C., Nitsch, R. M., Masliah, E., Growdon, J. H., et al. (2010) · Brain · doi:10.1093/brain/awq056 · Cited by 159 · cited 1×
“Followup autopsy analysis of subjects in the AN1792 trial who had generated measurable titers against Ab42 demonstrated a striking removal of Ab from brain parenchyma as well as amelioration of neurite abnormalities and hippocampal tau pathology similar to the results documented in preclinical animal studies [72,73].”
ResultPK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET
Venneti, S., Lopresti, B. J., Wang, G., Hamilton, R. L., Mathis, C. A., Klunk, W. E., Apte, U. M., & Wiley, C. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.005 · Cited by 138
Maeda, J., Zhang, M.-R., Okauchi, T., Ji, B., Ono, M., Hattori, S., Kumata, K., Iwata, N., Saido, T. C., Trojanowski, J. Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3076-10.2011 · Cited by 136
Sun, S.-W., Song, S.-K., Harms, M. P., Lin, S.-J., Holtzman, D. M., Merchant, K. M., & Kotyk, J. J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.09.006 · Cited by 121
Neuroinflammation‐induced acceleration of amyloid deposition in the APPV717F transgenic mouse
Qiao, X., Cummins, D. J., & Paul, S. M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01666.x · Cited by 119 · cited 1×
“However, microglia may also produce detrimental pro-inflammatory cytokines that impede efficient Ab clearance, promote tau phosphorylation, neuronal injury and cognitive impairment [94-96].”
BackgroundWang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · cited 3×
“In support of this proposal, a significant amount of anti-Ab antibody decorating plaques has been observed [47,75].”
BackgroundFaure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober, F., Dhenain, M., Rampon, C., & Delatour, B. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.009 · Cited by 112
Hong, S., Quintero-Monzon, O., Ostaszewski, B. L., Podlisny, D. R., Cavanaugh, W. T., Yang, T., Holtzman, D. M., Cirrito, J. R., & Selkoe, D. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3272-11.2011 · Cited by 111
Alexandru, A., Jagla, W., Graubner, S., Becker, A., Bäuscher, C., Kohlmann, S., Sedlmeier, R., Raber, K. A., Cynis, H., Rönicke, R., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1794-11.2011 · Cited by 102
Yang, D., Xie, Z., Stephenson, D., Morton, D., Hicks, C. D., Brown, T. M., Sriram, R., O'Neill, S., Raunig, D., & Bocan, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.067 · Cited by 64 · cited 1×
“Volumetric magnetic resonance imaging (vMRI) of AD subjects is routinely used in clinical trials and similar vMRI endpoints have been utilized to characterize the significant volume loss in both the hippocampus and cortex in the Tg4510 tau transgenic mouse model that was also correlated with the aggressive neurodegene…”
MethodAbramowski, D., Rabe, S., Upadhaya, A. R., Reichwald, J., Danner, S., Staab, D., Capetillo-Zarate, E., Yamaguchi, H., Saido, T. C., Wiederhold, K.-H., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4586-11.2012 · Cited by 41 · cited 1×
“Recently, transgenic mice that over-express Ab42 in the endoplasmic reticulum demonstrate overt neurodegeneration in the hippocampal CA1 region; however, identification of neurons in the AD brain with intraneuronal accumulation of Ab is difficult [86].”
BackgroundVisualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Higuchi, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602906 · Cited by 34
Duncan, M. J. (2006) · Neuroembryology and Aging · doi:10.1159/000103735 · Cited by 14
Cited by
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model
Li, T., Braunstein, K. E., Zhang, J., Lau, A., Sibener, L., Deeble, C., & Wong, P. C. (2016) · Nature Communications · doi:10.1038/ncomms12082 · Cited by 114
Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
Stevens, L. M., & Brown, R. E. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.10.033 · Cited by 92
Metadata
- Authors
- Bales, K. R.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2012-02-23
- Volume
- 7
- Issue
- 4
- Pages
- 281-297
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W1997738202
- Cited by
- 45
- References
- 67
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.